Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 8, 2025

Is L3Harris the Best Defense Play Amid Increased Military Spending?

View original at finance.yahoo.com
Is L3Harris the Best Defense Play Amid Increased Military Spending? This article first appeared on GuruFocus. L3Harris Technologies (NYSE: LHX) may not carry the household name status of defence giants Lockheed or Raytheon, but I wouldn't mistake that for irrelevance…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Aerojet acquisition de-risks L3Harris business by adding long-cycle, platform-agnostic revenue stream

    80% confidence
  • L3Harris guidance represents about 7% growth in EPS

    80% confidence
  • L3Harris is initiating a Buy rating

    80% confidence
  • Wall Street has Strong Buy rating overall on L3Harris

    80% confidence
  • Several analysts see upside to $280 range with some looking down to $212

    80% confidence
  • Forward EPS guidance appears conservative given strong order momentum and robust defense budget

    80% confidence
  • L3Harris may be underestimated by the market despite being well-positioned strategically

    80% confidence
  • Recent analyst downward revisions tied to accounting adjustments, not underlying demand issues

    80% confidence
  • L3Harris offers compelling mix of quality and growth, recommendation is Buy

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com